Retail prices of 44 formulations fixed by NPPA
New Delhi: National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 44 formulations including those indicated for the treatment of hypertension, depression, high blood sugar levels caused by type 2 diabetes, etc under Drugs (Prices Control) Order, 2013.The price fixation is based on the decision of 115th Authority meeting dated 31.07.2023.The drugs whose prices have been...
New Delhi: National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 44 formulations including those indicated for the treatment of hypertension, depression, high blood sugar levels caused by type 2 diabetes, etc under Drugs (Prices Control) Order, 2013.
The price fixation is based on the decision of 115th Authority meeting dated 31.07.2023.
The drugs whose prices have been fixed include MSN Labs and Sanofi India's Sitagliptin Phosphate and Metformin Hydrochloride Tablets, Akum Drugs & Pharma and Mankind Pharma's Levetiracetam, Sodium Chloride Infusion, Akums Drugs & Pharma and Abbott Healthcare's Aceclofeanc, Paracetamol & Serratiopeptidase Tablet, Akums Drugs & Pharma and Cipla's Chlorthalidone, Amlodipine & Telmisartan Tablets.
The list further includes Synokem Lifesciences and Mankind Pharma's Linagliptin plus Metformin Hydrochloride Tablet, Hetero Labs and Sun Pharma's Cefuroxime Axetil Tablets, Akums Drugs & Pharma and Ipca Labs's Azelnidipine and Telmisartan Tablet.
| Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Paroxetine Controlled release & Clonazepam Capsules | Each hard gelatin capsule contains: Paroxetine Hydrochloride IP eq. to Paroxetine 12.5mg (As enteric coated controlled release tablet) Clonazepam IP 0.5mg (as immediate release tablet) | 1 Capsule | M/s Akum Drugs & Pharmaceuticals Ltd. / M/s Eris Lifesciences Limited | 14.53 |
| 2 | Itraconazole Capsule (Supra- Bioavailable formulation) | Each Capsule contains: Itraconazole IP 65mg | 1 Capsule | M/s Mascot Health Series Pvt. Ltd. / M/s Health SpecialitiesPvt. Ltd. | 12.06 |
| 3 | Levetiracetam, Sodium Chloride Infusion | Each 100ml contains: Levetiracetam IP 500mg Sodium Chloride IP 820mg | 1 ml | M/s Akum Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. | 0.89 |
| 4 | Sitagliptin Phosphate and Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s Sanofi India Limited | 10.82 |
|
5 | Sitagliptin Phosphate and Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s Sanofi India Limited | 9.21 |
| 6 | Telmisartan and Cilnidipine Tablet | Each film coated tablet contains: Telmisartan IP 40mg Cilnidipine IP 10mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Indchemie Health Specialities Pvt. Ltd. | 10.12 |
| 7 | Aceclofeanc, Paracetamol & Serratiopeptidas e Tablet | Each film coated tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coated granules eq. to 30000 enzyme activity unit of serratiopeptidase) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Abbott Healthcare Pvt. Ltd. | 8.38 |
| 8 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 6.25mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 40mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 10.34 |
| 9 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 12.5mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 40mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 10.24 |
| 10 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 6.25mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 80mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 16.77 |
| 11 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 12.5mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 80mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 15.20 |
| 12 | Levocetirizine, Montelukast & (SR) Ambroxol Hydrochloride Tablets | Each uncoated bilayered tablet contains: Levocetirizine Hydrochloride IP 5mg Montelukast Sodium IP eq. to Montelukast 10mg Ambroxol Hydrochloride IP 75mg (As sustained Release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 15.89 |
| 13 | Rabeprazole Sodium and Ondansetron Tablets | Each Film coated tablet contains: Rabeprazole Sodium IP 20mg (As Enteric Coated Form) Ondansetron Hydrochloride IP eq. to Ondansetron 4mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 6.83 |
| 14 | Vitamin D3 Oral Solution | Each 5ml contains: Cholecalciferol IP 60000IU (In Nano Droplet form) | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Eris Lifesciences Limited | 11.94 |
| 15 | Glimepiride, Voglibose & Metformin Hydrochloride (as Extended- release form) tablet | Each uncoated Bilayered tablet contains: Glimepiride IP 1mg Voglibose IP 0.2mg Metformin Hydrochloride IP 1000mg (As Extended Release) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited | 11.83 |
| 16 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Synokem Lifesciences Pvt. Ltd. / M/s Mankind Pharma Ltd. | 8.97 |
| 17 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Synokem Lifesciences Pvt. Ltd. / M/s Mankind Pharma Ltd. | 9.60 |
| 18 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 9.60 |
| 19 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 8.97 |
| 20 | Paracetamol, Phenylepherine Hydrochloride and Chlorphenirami ne Maleate Syrup | Each 5ml contains: Paracetamol IP 250mg Phenylepherine Hydrochloride 5mg Chlorpheniramine Maleate IP 2mg | 1 ML | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Micro Labs Limited | 1.21 |
| 21 | Glimepiride, Voglibose & Metformin Hydrochloride (as Extended- release form) tablet | Each uncoated Bilayered tablet contains: Glimepiride IP 2mg Voglibose IP 0.2mg Metformin Hydrochloride IP 1000mg (As Extended Release) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited | 13.37 |
| 22 | Diclofenac Diethylamine, Methyl Salicylate & Menthol Topical Gel | Composition: Diclofenac Diethylamine IP 2.32% (eq. to Diclofenac Sodium 2% w/w) Methyl Salicylate IP 10 % w/w Menthol IP 5% w/w | 1 Gram | M/s Pontika Aerotech Limited / M/s Intas Pharmaceuticals Ltd. | 4.08 |
| 23 | Faropenem Sodium & Potassium Clavulanate Tablets | Each film coated tablet contains: Faropenem Sodium eq. to Faropenem 200mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 90.28 |
| 24 | Pantoprazole Dual-release Gastro-resistant Tablet | Each Dual-release Gastro- resistant tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 80mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd. | 13.39 |
| 25 | Tacrolimus Capsule | Each hard gelatin capsule contains: Tacrolimus IP eq. to Anhydrous Tacrolimus 0.25mg | 1 Capsule | M/s Rivpra Formulation Pvt. Ltd. / M/s RPG Life Sciences Ltd. | 11.05 |
| 26 | Clobazam Oral Suspension | Each ml of the suspension contains: Clobazam IP 2.5mg | 1 ml | M/s Windlas Biotech Limited / M/s Sanofi India Limited | 2.42 |
| 27 | Cefuroxime Axetil Tablets | Each film coated tablet contains: Cefuroxime Axetil eq. to Cefuroxime 250mg | 1 Tablet | M/s Hetero Labs Limited / M/s Sun Pharmaceuticals Industries Limited | 25.69 |
| 28 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Corona Remedies Pvt. Ltd. | 8.97 |
| 29 | Amoxycillin and Potassium Clavulanate Oral Suspension (Combi pack with Sterile Water for Reconstitution of Dry Syrup) | Each combi pack contains: A. Amoxycillin and Potassium Clavulanate Oral suspension IP Composition: Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg B. 2 Ampoules of sterile water for reconstitution of dry syrup each ampoule contains: sterile water for injection IP 25ml | Each Combi Pack | M/s Malik Lifesciences Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 162.11 |
| 30 | Clarithromycin for Oral Suspension USP | Each 5 ml of Reconstituted suspension contains: Clarithromycin IP 250mg | 1 ml | M/s Vapi Care Pharma Pvt. Ltd. / M/s Mankind Pharma Ltd. | 6.09 |
| 31 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 8.97 |
| 32 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 9.60 |
| 33 | Oral Rehydration Salts with Zinc | Each sachet contains: Zinc Sulphate Monohydrate IP 0.011g Sodium Citrate IP 0.58g Potassium Chloride IP 0.30g Sodium Chloride IP 0.52g Dextrose Anhydrous IP 2.70g | 1 Sachet of 4.4 gram | M/s Acme Diet Care Pvt. Ltd. / M/s Alkem Laboratories Limited | 6.12 |
| 34 | Cefixime Oral Suspension IP | Each 5ml of reconstituted suspension contains: Cefixime IP (As Trihydrate) eq. to Anhydrous Cefixime 200mg | 1 ml | M/s Alkem Healthscience (A unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd. | 4.06 |
| 35 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 11.01 |
| 36 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 13.12 |
| 37 | Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Vildagliptin (As Sustained release form) IP 100mg Metformin Hydrochloride (as Sustained Release form) IP 1000mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 13.81 |
| 38 | Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release form) IP 500mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 12.27 |
| 39 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release form) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Alkem Laboratories Ltd. | 13.81 |
| 40 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Micro Labs Ltd. | 12.27 |
| 41 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Alkem Laboratories Ltd. | 12.27 |
| 42 | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Micro Labs Ltd. | 13.81 |
| 43 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release form) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 20.14 |
| 44 | Azelnidipine and Telmisartan Tablet | Each film coated tablet contains: Azelnidipine IP 16mg Telmisartan IP 40mg. | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Ipca Laboratories Limited | 17.96 |
The notification further reads,
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official notice, click on the following link:
https://medicaldialogues.in/pdf_upload/retail-44-english-222100.pdf
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd